Jade Biosciences, Inc. Net Income (Loss) Attributable to Parent, Diluted
Jade Biosciences, Inc. (JBIO) reported Net Income (Loss) Attributable to Parent, Diluted of -$55.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-08-10
- Jade Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-06-30 was -$55.77M.
- Jade Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2026-03-31 was -$40.37M.
- Jade Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-12-31 was -$31.93M.
- Jade Biosciences, Inc. net income (loss) attributable to parent, diluted for the quarter ending 2025-09-30 was -$25.18M.
- Jade Biosciences, Inc. net income (loss) attributable to parent, diluted for fiscal 2025 was -$127.41M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 0 month | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$55.77M 10-Q · filed 2026-08-10 | -$96.13M 10-Q · filed 2026-08-10 | -$128.06M derived: sum of 3 quarters · filed 2026-08-10 | -$153.24M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$40.37M 10-Q · filed 2026-05-07 | -$72.30M derived: sum of 2 quarters · filed 2026-05-07 | -$97.47M derived: sum of 3 quarters · filed 2026-05-07 | -$129.61M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | -$31.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$57.11M derived: sum of 2 quarters · filed 2026-03-06 | -$89.24M derived: sum of 3 quarters · filed 2026-08-10 | -$127.41M 10-K · filed 2026-03-06 | |
| 2025-09-30 | -$25.18M 10-Q · filed 2025-11-14 | -$57.31M derived: sum of 2 quarters · filed 2026-08-10 | -$95.48M 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | -$32.13M 10-Q · filed 2026-08-10 | -$70.30M 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | -$30.11M derived: 10-K 6 month − 10-Q 3 month · filed 2026-03-06 | -$46.98M 10-K · filed 2026-03-06 | |||
| 2024-09-30 | -$16.28M 10-Q · filed 2025-11-14 | ||||
| 2024-06-30 | -$590.00K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |